CN116162282A - Antibacterial and antiviral structure - Google Patents
Antibacterial and antiviral structure Download PDFInfo
- Publication number
- CN116162282A CN116162282A CN202111410009.6A CN202111410009A CN116162282A CN 116162282 A CN116162282 A CN 116162282A CN 202111410009 A CN202111410009 A CN 202111410009A CN 116162282 A CN116162282 A CN 116162282A
- Authority
- CN
- China
- Prior art keywords
- antiviral
- active ingredient
- antibacterial
- zinc
- antimicrobial
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000000840 anti-viral effect Effects 0.000 title claims abstract description 157
- 230000000844 anti-bacterial effect Effects 0.000 title claims abstract description 123
- 239000004480 active ingredient Substances 0.000 claims abstract description 139
- 239000000758 substrate Substances 0.000 claims abstract description 85
- 239000000463 material Substances 0.000 claims abstract description 63
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 claims abstract description 46
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 claims abstract description 32
- 229910052709 silver Inorganic materials 0.000 claims abstract description 32
- 239000004332 silver Substances 0.000 claims abstract description 32
- 239000004408 titanium dioxide Substances 0.000 claims abstract description 22
- 150000001875 compounds Chemical class 0.000 claims abstract description 16
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims abstract description 14
- 229910052725 zinc Inorganic materials 0.000 claims abstract description 14
- 239000011701 zinc Substances 0.000 claims abstract description 14
- 239000000203 mixture Substances 0.000 claims description 32
- 230000000845 anti-microbial effect Effects 0.000 claims description 29
- 239000000835 fiber Substances 0.000 claims description 28
- ONDPHDOFVYQSGI-UHFFFAOYSA-N zinc nitrate Chemical group [Zn+2].[O-][N+]([O-])=O.[O-][N+]([O-])=O ONDPHDOFVYQSGI-UHFFFAOYSA-N 0.000 claims description 20
- 239000011247 coating layer Substances 0.000 claims description 13
- 229920000642 polymer Polymers 0.000 claims description 11
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 claims description 10
- 239000011248 coating agent Substances 0.000 claims description 10
- 238000000576 coating method Methods 0.000 claims description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 10
- 239000004599 antimicrobial Substances 0.000 claims description 9
- VNDYJBBGRKZCSX-UHFFFAOYSA-L zinc bromide Chemical compound Br[Zn]Br VNDYJBBGRKZCSX-UHFFFAOYSA-L 0.000 claims description 8
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 claims description 8
- UAYWVJHJZHQCIE-UHFFFAOYSA-L zinc iodide Chemical compound I[Zn]I UAYWVJHJZHQCIE-UHFFFAOYSA-L 0.000 claims description 8
- 239000010410 layer Substances 0.000 claims description 7
- ZOIORXHNWRGPMV-UHFFFAOYSA-N acetic acid;zinc Chemical compound [Zn].CC(O)=O.CC(O)=O ZOIORXHNWRGPMV-UHFFFAOYSA-N 0.000 claims description 5
- WGIWBXUNRXCYRA-UHFFFAOYSA-H trizinc;2-hydroxypropane-1,2,3-tricarboxylate Chemical compound [Zn+2].[Zn+2].[Zn+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O WGIWBXUNRXCYRA-UHFFFAOYSA-H 0.000 claims description 5
- 239000004246 zinc acetate Substances 0.000 claims description 5
- 239000011746 zinc citrate Substances 0.000 claims description 5
- 235000006076 zinc citrate Nutrition 0.000 claims description 5
- 229940068475 zinc citrate Drugs 0.000 claims description 5
- 239000011787 zinc oxide Substances 0.000 claims description 5
- FMRLDPWIRHBCCC-UHFFFAOYSA-L Zinc carbonate Chemical compound [Zn+2].[O-]C([O-])=O FMRLDPWIRHBCCC-UHFFFAOYSA-L 0.000 claims description 4
- 239000004417 polycarbonate Substances 0.000 claims description 4
- 229920000515 polycarbonate Polymers 0.000 claims description 4
- 229910052708 sodium Inorganic materials 0.000 claims description 4
- 239000011734 sodium Substances 0.000 claims description 4
- BIKXLKXABVUSMH-UHFFFAOYSA-N trizinc;diborate Chemical compound [Zn+2].[Zn+2].[Zn+2].[O-]B([O-])[O-].[O-]B([O-])[O-] BIKXLKXABVUSMH-UHFFFAOYSA-N 0.000 claims description 4
- GAAKLDANOSASAM-UHFFFAOYSA-N undec-10-enoic acid;zinc Chemical compound [Zn].OC(=O)CCCCCCCCC=C GAAKLDANOSASAM-UHFFFAOYSA-N 0.000 claims description 4
- 229940102001 zinc bromide Drugs 0.000 claims description 4
- 239000011667 zinc carbonate Substances 0.000 claims description 4
- 235000004416 zinc carbonate Nutrition 0.000 claims description 4
- 229910000010 zinc carbonate Inorganic materials 0.000 claims description 4
- 239000011592 zinc chloride Substances 0.000 claims description 4
- 235000005074 zinc chloride Nutrition 0.000 claims description 4
- 229940043810 zinc pyrithione Drugs 0.000 claims description 4
- GAWWVVGZMLGEIW-GNNYBVKZSA-L zinc ricinoleate Chemical compound [Zn+2].CCCCCC[C@@H](O)C\C=C/CCCCCCCC([O-])=O.CCCCCC[C@@H](O)C\C=C/CCCCCCCC([O-])=O GAWWVVGZMLGEIW-GNNYBVKZSA-L 0.000 claims description 4
- 229940100530 zinc ricinoleate Drugs 0.000 claims description 4
- 229940118257 zinc undecylenate Drugs 0.000 claims description 4
- PICXIOQBANWBIZ-UHFFFAOYSA-N zinc;1-oxidopyridine-2-thione Chemical compound [Zn+2].[O-]N1C=CC=CC1=S.[O-]N1C=CC=CC1=S PICXIOQBANWBIZ-UHFFFAOYSA-N 0.000 claims description 4
- RXBXBWBHKPGHIB-UHFFFAOYSA-L zinc;diperchlorate Chemical compound [Zn+2].[O-]Cl(=O)(=O)=O.[O-]Cl(=O)(=O)=O RXBXBWBHKPGHIB-UHFFFAOYSA-L 0.000 claims description 4
- ZPEJZWGMHAKWNL-UHFFFAOYSA-L zinc;oxalate Chemical compound [Zn+2].[O-]C(=O)C([O-])=O ZPEJZWGMHAKWNL-UHFFFAOYSA-L 0.000 claims description 4
- 239000004814 polyurethane Substances 0.000 claims description 3
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 claims description 3
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 2
- 239000002245 particle Substances 0.000 claims description 2
- 229920002635 polyurethane Polymers 0.000 claims description 2
- 229960001939 zinc chloride Drugs 0.000 claims description 2
- 229960001296 zinc oxide Drugs 0.000 claims description 2
- 238000012360 testing method Methods 0.000 description 60
- 241000700605 Viruses Species 0.000 description 35
- SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(1+) nitrate Chemical compound [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 description 32
- 239000007788 liquid Substances 0.000 description 26
- 230000001580 bacterial effect Effects 0.000 description 17
- 230000000052 comparative effect Effects 0.000 description 17
- 229910001961 silver nitrate Inorganic materials 0.000 description 16
- -1 tile Substances 0.000 description 9
- 241000588724 Escherichia coli Species 0.000 description 8
- 241000894006 Bacteria Species 0.000 description 7
- 239000011521 glass Substances 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 229920002799 BoPET Polymers 0.000 description 6
- 239000006260 foam Substances 0.000 description 6
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 5
- 239000012153 distilled water Substances 0.000 description 4
- 239000003480 eluent Substances 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 230000001954 sterilising effect Effects 0.000 description 4
- JKFYKCYQEWQPTM-UHFFFAOYSA-N 2-azaniumyl-2-(4-fluorophenyl)acetate Chemical compound OC(=O)C(N)C1=CC=C(F)C=C1 JKFYKCYQEWQPTM-UHFFFAOYSA-N 0.000 description 3
- 229910021612 Silver iodide Inorganic materials 0.000 description 3
- FOIXSVOLVBLSDH-UHFFFAOYSA-N Silver ion Chemical compound [Ag+] FOIXSVOLVBLSDH-UHFFFAOYSA-N 0.000 description 3
- 238000002832 anti-viral assay Methods 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 229920003023 plastic Polymers 0.000 description 3
- 239000004033 plastic Substances 0.000 description 3
- 229940045105 silver iodide Drugs 0.000 description 3
- YPNVIBVEFVRZPJ-UHFFFAOYSA-L silver sulfate Chemical compound [Ag+].[Ag+].[O-]S([O-])(=O)=O YPNVIBVEFVRZPJ-UHFFFAOYSA-L 0.000 description 3
- 229910000367 silver sulfate Inorganic materials 0.000 description 3
- 238000004659 sterilization and disinfection Methods 0.000 description 3
- ZXSQEZNORDWBGZ-UHFFFAOYSA-N 1,3-dihydropyrrolo[2,3-b]pyridin-2-one Chemical compound C1=CN=C2NC(=O)CC2=C1 ZXSQEZNORDWBGZ-UHFFFAOYSA-N 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- 241000711573 Coronaviridae Species 0.000 description 2
- 229920000742 Cotton Polymers 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- 239000004743 Polypropylene Substances 0.000 description 2
- 229910021607 Silver chloride Inorganic materials 0.000 description 2
- 239000008272 agar Substances 0.000 description 2
- 239000000919 ceramic Substances 0.000 description 2
- 238000012790 confirmation Methods 0.000 description 2
- 238000003618 dip coating Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 239000002105 nanoparticle Substances 0.000 description 2
- 239000000123 paper Substances 0.000 description 2
- 229920000728 polyester Polymers 0.000 description 2
- 229920000573 polyethylene Polymers 0.000 description 2
- 229920001155 polypropylene Polymers 0.000 description 2
- CQLFBEKRDQMJLZ-UHFFFAOYSA-M silver acetate Chemical compound [Ag+].CC([O-])=O CQLFBEKRDQMJLZ-UHFFFAOYSA-M 0.000 description 2
- 229940071536 silver acetate Drugs 0.000 description 2
- LKZMBDSASOBTPN-UHFFFAOYSA-L silver carbonate Substances [Ag].[O-]C([O-])=O LKZMBDSASOBTPN-UHFFFAOYSA-L 0.000 description 2
- 229910001958 silver carbonate Inorganic materials 0.000 description 2
- USOFCTBGGPGUEF-UHFFFAOYSA-N silver hypochlorite Chemical compound [Ag+].[O-]Cl USOFCTBGGPGUEF-UHFFFAOYSA-N 0.000 description 2
- HKZLPVFGJNLROG-UHFFFAOYSA-M silver monochloride Chemical compound [Cl-].[Ag+] HKZLPVFGJNLROG-UHFFFAOYSA-M 0.000 description 2
- XNGYKPINNDWGGF-UHFFFAOYSA-L silver oxalate Chemical compound [Ag+].[Ag+].[O-]C(=O)C([O-])=O XNGYKPINNDWGGF-UHFFFAOYSA-L 0.000 description 2
- FJOLTQXXWSRAIX-UHFFFAOYSA-K silver phosphate Chemical compound [Ag+].[Ag+].[Ag+].[O-]P([O-])([O-])=O FJOLTQXXWSRAIX-UHFFFAOYSA-K 0.000 description 2
- 229940019931 silver phosphate Drugs 0.000 description 2
- 229910000161 silver phosphate Inorganic materials 0.000 description 2
- 229960003600 silver sulfadiazine Drugs 0.000 description 2
- 229910001494 silver tetrafluoroborate Inorganic materials 0.000 description 2
- UEJSSZHHYBHCEL-UHFFFAOYSA-N silver(1+) sulfadiazinate Chemical compound [Ag+].C1=CC(N)=CC=C1S(=O)(=O)[N-]C1=NC=CC=N1 UEJSSZHHYBHCEL-UHFFFAOYSA-N 0.000 description 2
- CLDWGXZGFUNWKB-UHFFFAOYSA-M silver;benzoate Chemical compound [Ag+].[O-]C(=O)C1=CC=CC=C1 CLDWGXZGFUNWKB-UHFFFAOYSA-M 0.000 description 2
- FTNNQMMAOFBTNJ-UHFFFAOYSA-M silver;formate Chemical compound [Ag+].[O-]C=O FTNNQMMAOFBTNJ-UHFFFAOYSA-M 0.000 description 2
- CYLMOXYXYHNGHZ-UHFFFAOYSA-M silver;propanoate Chemical compound [Ag+].CCC([O-])=O CYLMOXYXYHNGHZ-UHFFFAOYSA-M 0.000 description 2
- 238000005507 spraying Methods 0.000 description 2
- 239000004753 textile Substances 0.000 description 2
- ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 description 2
- 239000002023 wood Substances 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 235000012766 Cannabis sativa ssp. sativa var. sativa Nutrition 0.000 description 1
- 235000012765 Cannabis sativa ssp. sativa var. spontanea Nutrition 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 229910021610 Silver(III) fluoride Inorganic materials 0.000 description 1
- 229920002334 Spandex Polymers 0.000 description 1
- 239000004809 Teflon Substances 0.000 description 1
- 229920006362 Teflon® Polymers 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 235000009120 camo Nutrition 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 235000005607 chanvre indien Nutrition 0.000 description 1
- CZKMPDNXOGQMFW-UHFFFAOYSA-N chloro(triethyl)germane Chemical compound CC[Ge](Cl)(CC)CC CZKMPDNXOGQMFW-UHFFFAOYSA-N 0.000 description 1
- 238000004891 communication Methods 0.000 description 1
- 238000005034 decoration Methods 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- WGAKFMRZYUGMGU-UHFFFAOYSA-L disilver;selenate Chemical compound [Ag+].[Ag+].[O-][Se]([O-])(=O)=O WGAKFMRZYUGMGU-UHFFFAOYSA-L 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 239000011487 hemp Substances 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000010985 leather Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- QSUXJUWWFGMXGD-UHFFFAOYSA-N nitric acid oxosilver Chemical compound [Ag]=O.O[N+]([O-])=O QSUXJUWWFGMXGD-UHFFFAOYSA-N 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 239000004800 polyvinyl chloride Substances 0.000 description 1
- 230000001902 propagating effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000005060 rubber Substances 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 150000003378 silver Chemical class 0.000 description 1
- IMGNYAPMSDUASV-UHFFFAOYSA-K silver arsenate Chemical compound [Ag+].[Ag+].[Ag+].[O-][As]([O-])([O-])=O IMGNYAPMSDUASV-UHFFFAOYSA-K 0.000 description 1
- ADZWSOLPGZMUMY-UHFFFAOYSA-M silver bromide Chemical compound [Ag]Br ADZWSOLPGZMUMY-UHFFFAOYSA-M 0.000 description 1
- 229940071575 silver citrate Drugs 0.000 description 1
- KKKDGYXNGYJJRX-UHFFFAOYSA-M silver nitrite Chemical compound [Ag+].[O-]N=O KKKDGYXNGYJJRX-UHFFFAOYSA-M 0.000 description 1
- 229910001923 silver oxide Inorganic materials 0.000 description 1
- NDVLTYZPCACLMA-UHFFFAOYSA-N silver oxide Substances [O-2].[Ag+].[Ag+] NDVLTYZPCACLMA-UHFFFAOYSA-N 0.000 description 1
- WYCFMBAHFPUBDS-UHFFFAOYSA-L silver sulfite Chemical compound [Ag+].[Ag+].[O-]S([O-])=O WYCFMBAHFPUBDS-UHFFFAOYSA-L 0.000 description 1
- PGGQSYHSNJQLOQ-UHFFFAOYSA-K silver trifluoride Chemical compound F[Ag](F)F PGGQSYHSNJQLOQ-UHFFFAOYSA-K 0.000 description 1
- QZRSVBDWRWTHMT-UHFFFAOYSA-M silver;3-carboxy-3,5-dihydroxy-5-oxopentanoate Chemical compound [Ag+].OC(=O)CC(O)(C([O-])=O)CC(O)=O QZRSVBDWRWTHMT-UHFFFAOYSA-M 0.000 description 1
- 239000004759 spandex Substances 0.000 description 1
- 239000004575 stone Substances 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- QUTYHQJYVDNJJA-UHFFFAOYSA-K trisilver;2-hydroxypropane-1,2,3-tricarboxylate Chemical compound [Ag+].[Ag+].[Ag+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QUTYHQJYVDNJJA-UHFFFAOYSA-K 0.000 description 1
- 210000002268 wool Anatomy 0.000 description 1
- RCQZCHPRZSTYAX-UHFFFAOYSA-N zinc tetrahydrate Chemical compound O.O.O.O.[Zn] RCQZCHPRZSTYAX-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J9/00—Working-up of macromolecular substances to porous or cellular articles or materials; After-treatment thereof
- C08J9/36—After-treatment
- C08J9/365—Coating
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J9/00—Working-up of macromolecular substances to porous or cellular articles or materials; After-treatment thereof
- C08J9/36—After-treatment
- C08J9/40—Impregnation
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J9/00—Working-up of macromolecular substances to porous or cellular articles or materials; After-treatment thereof
- C08J9/36—After-treatment
- C08J9/40—Impregnation
- C08J9/42—Impregnation with macromolecular compounds
-
- D—TEXTILES; PAPER
- D06—TREATMENT OF TEXTILES OR THE LIKE; LAUNDERING; FLEXIBLE MATERIALS NOT OTHERWISE PROVIDED FOR
- D06M—TREATMENT, NOT PROVIDED FOR ELSEWHERE IN CLASS D06, OF FIBRES, THREADS, YARNS, FABRICS, FEATHERS OR FIBROUS GOODS MADE FROM SUCH MATERIALS
- D06M11/00—Treating fibres, threads, yarns, fabrics or fibrous goods made from such materials, with inorganic substances or complexes thereof; Such treatment combined with mechanical treatment, e.g. mercerising
- D06M11/58—Treating fibres, threads, yarns, fabrics or fibrous goods made from such materials, with inorganic substances or complexes thereof; Such treatment combined with mechanical treatment, e.g. mercerising with nitrogen or compounds thereof, e.g. with nitrides
- D06M11/64—Treating fibres, threads, yarns, fabrics or fibrous goods made from such materials, with inorganic substances or complexes thereof; Such treatment combined with mechanical treatment, e.g. mercerising with nitrogen or compounds thereof, e.g. with nitrides with nitrogen oxides; with oxyacids of nitrogen or their salts
- D06M11/65—Salts of oxyacids of nitrogen
-
- D—TEXTILES; PAPER
- D06—TREATMENT OF TEXTILES OR THE LIKE; LAUNDERING; FLEXIBLE MATERIALS NOT OTHERWISE PROVIDED FOR
- D06M—TREATMENT, NOT PROVIDED FOR ELSEWHERE IN CLASS D06, OF FIBRES, THREADS, YARNS, FABRICS, FEATHERS OR FIBROUS GOODS MADE FROM SUCH MATERIALS
- D06M15/00—Treating fibres, threads, yarns, fabrics, or fibrous goods made from such materials, with macromolecular compounds; Such treatment combined with mechanical treatment
- D06M15/19—Treating fibres, threads, yarns, fabrics, or fibrous goods made from such materials, with macromolecular compounds; Such treatment combined with mechanical treatment with synthetic macromolecular compounds
- D06M15/21—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds
- D06M15/263—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds of unsaturated carboxylic acids; Salts or esters thereof
-
- D—TEXTILES; PAPER
- D06—TREATMENT OF TEXTILES OR THE LIKE; LAUNDERING; FLEXIBLE MATERIALS NOT OTHERWISE PROVIDED FOR
- D06M—TREATMENT, NOT PROVIDED FOR ELSEWHERE IN CLASS D06, OF FIBRES, THREADS, YARNS, FABRICS, FEATHERS OR FIBROUS GOODS MADE FROM SUCH MATERIALS
- D06M15/00—Treating fibres, threads, yarns, fabrics, or fibrous goods made from such materials, with macromolecular compounds; Such treatment combined with mechanical treatment
- D06M15/19—Treating fibres, threads, yarns, fabrics, or fibrous goods made from such materials, with macromolecular compounds; Such treatment combined with mechanical treatment with synthetic macromolecular compounds
- D06M15/37—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
- D06M15/507—Polyesters
- D06M15/513—Polycarbonates
-
- D—TEXTILES; PAPER
- D06—TREATMENT OF TEXTILES OR THE LIKE; LAUNDERING; FLEXIBLE MATERIALS NOT OTHERWISE PROVIDED FOR
- D06M—TREATMENT, NOT PROVIDED FOR ELSEWHERE IN CLASS D06, OF FIBRES, THREADS, YARNS, FABRICS, FEATHERS OR FIBROUS GOODS MADE FROM SUCH MATERIALS
- D06M15/00—Treating fibres, threads, yarns, fabrics, or fibrous goods made from such materials, with macromolecular compounds; Such treatment combined with mechanical treatment
- D06M15/19—Treating fibres, threads, yarns, fabrics, or fibrous goods made from such materials, with macromolecular compounds; Such treatment combined with mechanical treatment with synthetic macromolecular compounds
- D06M15/37—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
- D06M15/564—Polyureas, polyurethanes or other polymers having ureide or urethane links; Precondensation products forming them
-
- D—TEXTILES; PAPER
- D06—TREATMENT OF TEXTILES OR THE LIKE; LAUNDERING; FLEXIBLE MATERIALS NOT OTHERWISE PROVIDED FOR
- D06M—TREATMENT, NOT PROVIDED FOR ELSEWHERE IN CLASS D06, OF FIBRES, THREADS, YARNS, FABRICS, FEATHERS OR FIBROUS GOODS MADE FROM SUCH MATERIALS
- D06M16/00—Biochemical treatment of fibres, threads, yarns, fabrics, or fibrous goods made from such materials, e.g. enzymatic
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J2300/00—Characterised by the use of unspecified polymers
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J2433/00—Characterised by the use of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and only one being terminated by only one carboxyl radical, or of salts, anhydrides, esters, amides, imides, or nitriles thereof; Derivatives of such polymers
- C08J2433/04—Characterised by the use of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and only one being terminated by only one carboxyl radical, or of salts, anhydrides, esters, amides, imides, or nitriles thereof; Derivatives of such polymers esters
- C08J2433/06—Characterised by the use of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and only one being terminated by only one carboxyl radical, or of salts, anhydrides, esters, amides, imides, or nitriles thereof; Derivatives of such polymers esters of esters containing only carbon, hydrogen, and oxygen, the oxygen atom being present only as part of the carboxyl radical
- C08J2433/10—Homopolymers or copolymers of methacrylic acid esters
- C08J2433/12—Homopolymers or copolymers of methyl methacrylate
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J2469/00—Characterised by the use of polycarbonates; Derivatives of polycarbonates
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J2475/00—Characterised by the use of polyureas or polyurethanes; Derivatives of such polymers
- C08J2475/04—Polyurethanes
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Textile Engineering (AREA)
- Polymers & Plastics (AREA)
- Medicinal Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Materials Engineering (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Microbiology (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Abstract
The invention provides an antibacterial and antiviral structure, which comprises a porous substrate and an antibacterial and antiviral material, wherein the antibacterial and antiviral material is combined on the porous substrate and is formed by a porous substrate, a porous substrate and a porous substrate, wherein the porous substrate is a porous substrate, and the antibacterial and antiviral material is a porous substrateThe porous substrate has 1-450g/m per unit surface area 2 Is a material having antibacterial and antiviral properties. The antibacterial and antiviral material comprises at least one of a first active ingredient and a second active ingredient, wherein the first active ingredient comprises a silver component and a zinc-containing compound, and the second active ingredient comprises a silver component and titanium dioxide. Therefore, the articles applied by the antibacterial and antiviral structure have excellent antibacterial and antiviral effects.
Description
Technical Field
The present invention relates to an antimicrobial structure, and more particularly to an antimicrobial and antiviral structure suitable for use in a variety of articles such as wearing articles where antimicrobial and antiviral requirements are present.
Background
Bacteria and viruses are ubiquitous in the daily living environment and are difficult to observe by naked eyes, and various diseases can be caused once the bacteria and viruses invade a human body. The global outbreak of new coronavirus epidemic situation in 2019 has high mutation speed and strong transmission capacity. With frequent population flow and social communication, epidemic situations of new coronaviruses are expanding continuously, and even pose a serious threat to human survival. However, the masks in the market such as medical masks, activated carbon masks, cotton masks, N95 masks, etc. can only filter and block most bacteria and viruses, and have no function of actually inhibiting antibacterial viruses.
Thus, there is a need in the marketplace for an antimicrobial and antiviral structure that kills pathogenic bacteria and viruses and prevents them from propagating, such that the bacteria and viruses cannot be transmitted.
Disclosure of Invention
The invention aims to solve the technical problem of providing an antibacterial and antiviral structure aiming at the defects in the prior art.
In order to solve the above problems, one of the technical solutions adopted in the present invention is to provide an antibacterial and antiviral structure comprising a porous substrate and an antibacterial and antiviral material, wherein the antibacterial and antiviral material is bonded to the porous substrate, and the porous substrate has a surface area per unit area of 1-450g/m 2 Is a material having antibacterial and antiviral properties. The antibacterial and antiviral material comprises at least one of a first active ingredient and a second active ingredient, wherein the first active ingredient comprises a silver component and a zinc-containing compound, and the second active ingredient comprises a silver component and titanium dioxide.
In one embodiment of the invention, the antimicrobial and antiviral structure further comprises an outer coating covering an outer surface of the porous substrate. When the antimicrobial antiviral material comprises only the first active ingredient, the first active ingredient is present in the outer cover.
In one embodiment of the present invention, the antibacterial and antiviral structure further comprises an outer coating layer covering an outer surface of the porous substrate, and the outer coating layer has an antibacterial and antiviral treatment surface. When the antibacterial and antiviral material contains both the first active ingredient and the second active ingredient, the first active ingredient is present in the outer cover and the second active ingredient is present on the antibacterial and antiviral treated surface.
In an embodiment of the invention, the outer coating layer is formed by a first composition, and the first composition includes the first active ingredient and a film-forming polymer. The silver component of the first active ingredient is present in the first composition in an amount of 10ppm to 1000ppm, and the zinc-containing compound of the first active ingredient is present in an amount of 1wt% to 10wt% and the film-forming polymer is present in an amount of 5wt% to 20wt% based on 100wt% of the first composition.
In an embodiment of the invention, the film-forming polymer is acrylic, polyurethane or polycarbonate.
In one embodiment of the present invention, the antimicrobial and antiviral treatment surface is formed by applying a second composition to an outer surface of the outer cover, the second composition comprising the second active ingredient and water. The silver component of the second active ingredient is contained in an amount of 0.001 to 1wt% and the titanium dioxide of the second active ingredient is contained in an amount of 0.01 to 2wt% based on 100wt% of the second composition.
In one embodiment of the present invention, the porous substrate is formed of a plurality of base fibers attached with the antibacterial and antiviral material.
In one embodiment of the present invention, a plurality of the base fibers are each covered by an outer cover. When the antibacterial and antiviral material contains only the first active ingredient, the first active ingredient is present in the outer cover of a plurality of the base fibers.
In one embodiment of the present invention, a plurality of the base fibers are each covered by an outer cover, wherein the outer cover has an antibacterial and antiviral treated surface. When the antibacterial and antiviral material contains both the first active ingredient and the second active ingredient, the first active ingredient is present in the outer coating layers of the plurality of base fibers, and the second active ingredient is present on the antibacterial and antiviral treated surface of the outer coating layers of the plurality of base fibers.
In one embodiment of the present invention, the zinc-containing compound of the first active ingredient is selected from zinc nitrate, sodium tetrahydroxy zincate, zinc chloride, zinc citrate, zinc undecylenate, zinc oxalate, zinc acetate, zinc carbonate, zinc iodide, zinc bromide, zinc pyrithione, zinc oxide, zinc ricinoleate, zinc borate, or zinc perchlorate.
In one embodiment of the invention, the titanium dioxide of the second active ingredient is in the form of particles and has a major axis of 10nm to 50nm and a minor axis of 3nm to 20nm.
The antibacterial and antiviral structure of the present invention can be bonded to the porous substrate by "the antibacterial and antiviral material is present in an amount of 1 to 450g/m per unit surface area of the porous substrate 2 The antibacterial and antiviral material of (a) and (b) comprises at least one of a first active ingredient and a second active ingredient, wherein the first active ingredient comprises a silver component and a zinc-containing compound, and the second active ingredient comprises a silver component and titanium dioxide, so that the antibacterial rate and the antiviral rate are both over 99%. In addition, the antibacterial and antiviral structure has the advantages of wide application range, flexible and convenient use, no harm to human bodies and environment and the like.
For a further understanding of the nature and the technical aspects of the present invention, reference should be made to the following detailed description of the invention and the accompanying drawings, which are provided for purposes of reference only and are not intended to limit the invention.
Drawings
Fig. 1 is a schematic view of an antibacterial and antiviral structure according to a first embodiment of the present invention.
Fig. 2 is another schematic diagram of an antibacterial and antiviral structure according to a first embodiment of the present invention.
Fig. 3 is a schematic view of an antibacterial and antiviral structure according to a second embodiment of the present invention.
Fig. 4 is a schematic view of an antibacterial and antiviral structure according to a third embodiment of the present invention.
Fig. 5A shows one possible embodiment of the base fiber with the antibacterial and antiviral material attached in the porous substrate of the antibacterial and antiviral structure of the third embodiment of the present invention.
Fig. 5B shows another possible embodiment of the base fiber with the antibacterial and antiviral material attached in the porous substrate of the antibacterial and antiviral structure of the third embodiment of the present invention.
Fig. 5C shows yet another possible embodiment of the base fiber with the antibacterial and antiviral material attached in the porous substrate of the antibacterial and antiviral structure of the third embodiment of the present invention.
Detailed Description
Bacteria and viruses are ubiquitous in daily living environments and cannot be observed with naked eyes, and diseases may be caused once the bacteria and viruses invade a human body, so the invention provides an antibacterial and antiviral structure which can be applied to various articles with antibacterial and antiviral requirements, such as wearing articles, decoration articles, carry-on articles and accessory articles, and endows the articles with excellent antibacterial and antiviral effects.
The following is a description of embodiments of the present invention disclosed herein with respect to "antibacterial and antiviral structures" and those skilled in the art will appreciate the advantages and effects of the present invention from the disclosure herein. The invention is capable of other and different embodiments and its several details are capable of modification and variation in various respects, all from the point of view and application, all without departing from the spirit of the present invention. The drawings of the present invention are merely schematic illustrations, and are not intended to be drawn to actual dimensions. The following embodiments will further illustrate the related art content of the present invention in detail, but the disclosure is not intended to limit the scope of the present invention. In addition, the term "or" as used herein shall include any one or combination of more of the associated listed items as the case may be.
First embodiment
Referring to fig. 1 and 2, a possible embodiment of an antibacterial and antiviral structure Z according to the present invention is shown. As shown in FIGS. 1 and 2, the antibacterial and antiviral structure Z of the present invention mainly comprises a porous substrate 1 and an antibacterial and antiviral material M bonded to the porous substrate 1, wherein 1-450g/M of antibacterial and antiviral material M is present per unit surface area of the porous substrate 1 2 An antibacterial and antiviral material M of (2). As the porous substrate 1 of the antibacterial and antiviral structure Z, a filter screen, porous ceramics, wood, sponge, synthetic wood, porous ceramic tile, stone, tile, leather, foam, paper, clothing, activated carbon, silica gel or teflon substrate may be used.
It should be noted that the antibacterial and antiviral material M may comprise at least one of a first active ingredient and a second active ingredient, wherein the first active ingredient comprises a silver component and a zinc-containing compound, and the second active ingredient comprises a silver component and titanium dioxide. Herein, the "active ingredient" of the antibacterial and antiviral material M refers to an ingredient that actually plays an antibacterial and antiviral role. When the antibacterial and antiviral material M contains the first active ingredient, the weight of the first active ingredient per unit surface area of the porous substrate 1 is 1-150g/M 2 The method comprises the steps of carrying out a first treatment on the surface of the When the antibacterial and antiviral material M contains the second active ingredient, the porous substrate 1 has a weight per unit surface area of the second active ingredient of 15 to 300g/M 2 . Therefore, the antibacterial and antiviral structure Z of the invention has good antibacterial and antiviral capability in both bright and dark places.
As shown in fig. 1, the antibacterial and antiviral structure Z of the present invention may further include an outer coating layer 2, and the outer coating layer 2 covers an outer surface 100 of the porous substrate 1, so that the antibacterial and antiviral material M is more firmly bonded to the porous substrate 1. Further, when the antibacterial and antiviral material M contains only the first active ingredient, the first active ingredient may be present in the outer cover 2. In addition, as shown in fig. 2, the outer cover 2 may further have an antibacterial and antiviral treatment surface 3, and when the antibacterial and antiviral material M contains both the first active ingredient and the second active ingredient, the first active ingredient may be present in the outer cover 2, and the second active ingredient may be present on the antibacterial and antiviral treatment surface 3. In practical use, the thickness of the outer coating layer 2 may be 100nm to 1500 μm, and the thickness of the antibacterial and antiviral treated surface 3 may be 10nm to 500nm.
From the above, the manner of bonding the antibacterial and antiviral material M to the porous substrate 1 is not particularly limited as long as the desired antibacterial and/or antiviral effect can be produced at the time of use. In some embodiments, the first active ingredient and/or the second active ingredient of the antimicrobial antiviral material M may be directly attached to the porous substrate 1. In an embodiment not shown, the outer coating 2 may have a double layer structure, wherein the first active ingredient of the antibacterial and antiviral material M is present in a first layer of the double layer structure and the second active ingredient is present in a second layer of the double layer structure.
Furthermore, the outer coating 2 may be formed of a first composition, which may be a polymer composition, i.e. the first composition may comprise a first active ingredient and a film-forming polymer; the film-forming polymer may be acryl, polyurethane (PU) or polycarbonate, but is not limited thereto. The silver component of the first active ingredient may be present in an amount of 10ppm to 1000ppm, the zinc-containing compound of the first active ingredient may be present in an amount of 1wt% to 10wt%, and the film-forming polymer may be present in an amount of 5wt% to 20wt%, based on the total weight of the first composition. In practice, the outer coating layer 2 may be formed by applying the first composition to the outer surface 100 of the porous substrate 1 by coating or impregnating and then curing it; in the outer coating 2, the silver component of the first active ingredient may be present in the form of a silver-containing compound or in the form of metallic silver (e.g., silver nanoparticles). The above description is only a viable embodiment and is not intended to limit the invention.
Examples of the silver-containing compound include: silver nitrate (silver nitrate), silver nitrite (silver nitrate), silver sulfate (silver sulfate), silver sulfite (silver sulfate), silver hypochlorite (silver hypochlorite), silver phosphate (silver phosphate), silver citrate (silver dihydrogen citrate), silver oxalate (silver oxalate), silver acetate (silver acetate), silver carbonate (silver carbonate), silver formate (silver format), silver benzoate (silver benzoate), silver propionate (silver propionate), silver selenate (silver select), silver tetrafluoroborate (silver tetrafluoroborate), silver chloride (silver chloride), silver bromide (silver iodide), silver iodide (silver iodide), silver arsenate (silver sulfonate), silver nitrate (silver oxide nitrate), silver trifluoride (III), triflate (silver (III), triflate (silver trifluoromethanesulfonate), and silver sulfadiazine (silver sulfadiazine). However, the present invention is not limited to the above examples.
Examples of the zinc-containing compound include: zinc perchlorate (zinc perchlorate), zinc nitrate (zinc nitrate), zinc citrate (zinc citrate), zinc oxalate (zinc oxalate), zinc acetate (zinc acetate), zinc borate (zinc borate), zinc carbonate (zinc carbonate), zinc ricinoleate (zinc ricinoleate), zinc undecylenate (zinc undecylenate), sodium tetrahydroxy zincate (sodium tetrahydroxozincate (2-), zinc chloride (zinc chloride), zinc iodide (zinc iodide), zinc bromide (zinc bromide), zinc pyrithione (zinc pyrithione), and zinc oxide (zinc oxide). The zinc-containing compound is preferably zinc citrate, zinc acetate or zinc oxide. However, the present invention is not limited to the above examples.
In some embodiments, the silver component of the first active ingredient may be present in the first composition in an amount of 10ppm, 50ppm, 100ppm, 200ppm, 300ppm, 400ppm, 500ppm, 600ppm, 700ppm, 800ppm, 900ppm, or 1000ppm. The zinc-containing compound of the first active ingredient may be present in the first composition in an amount of 1wt%, 2wt%, 3wt%, 4wt%, 5wt%, 6wt%, 7wt%, 8wt%, 9wt% or 10wt%. The film-forming polymer may be present in the first composition in an amount of 5wt%, 6wt%, 7wt%, 8wt%, 9wt%, 10wt%, 11wt%, 12wt%, 13wt%, 14wt%, 15wt%, 16wt%, 17wt%, 18wt%, 19wt% or 20wt%.
Alternatively, the antimicrobial and antiviral treated surface 3 of the outer cover 2 may be formed by treating the outer surface thereof with a second composition, which may be a dispersion of the active ingredient, i.e., the second composition may comprise the second active ingredient and water. The silver component of the second active ingredient may be present in an amount of 0.001wt% to 1wt%, the titanium dioxide of the second active ingredient may be present in an amount of 0.01wt% to 2wt%, and the remainder may be water, based on the total weight of the second composition. In practical application, the second composition can be uniformly applied on the outer surface of the outer coating layer 2 by spray coating, dip coating or roll coating, and after the second composition is dried, the second active ingredient is adhered on the outer surface of the outer coating layer 2 to form an antibacterial and antiviral treatment surface 3; on the antibacterial and antiviral treatment surface 3, the silver component of the second active ingredient is in the form of metallic silver (e.g., silver nanoparticles), and the titanium dioxide is in the form of anatase titanium dioxide nanoparticles, which preferably have a major axis of 10nm to 50nm and a minor axis of 3nm to 20nm. The above description is only a viable embodiment and is not intended to limit the invention.
In some embodiments, the silver component of the second active ingredient may be present in the second composition in an amount of 0.001wt%, 0.005wt%, 0.01wt%, 0.05wt%, 0.1wt%, 0.2wt%, 0.3wt%, 0.4wt%, 0.5wt%, 0.6wt%, 0.7wt%, 0.8wt%, 0.9wt% or 1wt%. The titanium dioxide of the second active ingredient may be present in the second composition in an amount of 0.01wt%, 0.05wt%, 0.1wt%, 0.2wt%, 0.3wt%, 0.4wt%, 0.5wt%, 0.6wt%, 0.7wt%, 0.8wt%, 0.9wt%, 1wt%, 1.1wt%, 1.2wt%, 1.3wt%, 1.4wt%, 1.5wt%, 1.6wt%, 1.7wt%, 1.8wt%, 1.9wt% or 2wt%.
Second embodiment
Referring to fig. 3, a variation of the antimicrobial and antiviral structure Z of the present invention is shown. As shown in fig. 3, the antibacterial and antiviral structure Z of the present invention mainly includes a porous substrate 1 and an antibacterial and antiviral material M, wherein the antibacterial and antiviral material M is bonded to the porous substrate 1. In the present embodiment, the antibacterial and antiviral material M contains only the second active ingredient, and the weight of the second active ingredient present per unit surface area of the porous substrate 1 is 15 to 300g/M 2 。
Further, the porous substrate 1 has an antibacterial and antiviral treatment surface 3, which may be formed by treating the outer surface of the porous substrate 1 with a second composition, which may be a dispersion of the active ingredient, i.e., the second composition may comprise the second active ingredient and water. The silver component of the second active ingredient may be present in an amount of 0.001wt% to 1wt%, the titanium dioxide of the second active ingredient may be present in an amount of 0.01wt% to 2wt%, and the remainder may be water, based on the total weight of the second composition.
In practical application, the second composition can be uniformly applied on the outer surface of the porous substrate 1 by spray coating, dip coating or roll coating, and after drying, the second active ingredient is adhered on the outer surface of the porous substrate 1 to form an antibacterial and antiviral treatment surface 3; on the antibacterial and antiviral treatment surface 3, the silver component of the second active ingredient is in the form of metallic silver (e.g., silver nanoparticles), and the titanium dioxide is in the form of anatase titanium dioxide nanoparticles, which preferably have a major axis of 10nm to 50nm and a minor axis of 3nm to 20nm. The above description is only a viable embodiment and is not intended to limit the invention.
The related technical details mentioned in the first embodiment are still valid in this embodiment, and in order to reduce repetition, they are not described here again. Accordingly, the related-art details mentioned in the present embodiment can also be applied to the first embodiment.
Third embodiment
Referring to fig. 4 in combination with fig. 5A to 5C, fig. 4 shows another alternative embodiment of the antibacterial and antiviral structure Z according to the present invention. As shown in fig. 4, the antibacterial and antiviral structure Z of the present invention mainly includes a porous substrate 1 and an antibacterial and antiviral material M, wherein the antibacterial and antiviral material M is bonded to the porous substrate 1. This embodiment is different from the foregoing embodiment in that the porous substrate 1 is constituted of a plurality of base fibers 11 attached with an antibacterial and antiviral material M. As the base fiber 11 of the porous substrate 1, polyester (PET), polyethylene (PE), polypropylene (PP), polyvinyl chloride (PVC), polyethylene vinyl acetate (PEVA), polycarbonate (PC), acetate, nylon, spandex, rubber, hemp, cotton, silk, glass, metal, carbon, wool, artificial protein, or paper fiber may be used.
In the present embodiment, when the antibacterial and antiviral material M contains only the first active ingredient, each of the plurality of base fibers 11 may be covered with an outer cover 2, as shown in fig. 5A, and the first active ingredient is present in the outer cover 2; when the antibacterial and antiviral material M contains both the first active ingredient and the second active ingredient, the outer cover 2 of each of the plurality of base fibers 11 may further have an antibacterial and antiviral treated surface 3, as shown in fig. 5B, and the second active ingredient is present on the antibacterial and antiviral treated surface 3. In addition, when the antibacterial and antiviral material M contains only the second active ingredient, each of the plurality of base fibers 11 has one antibacterial and antiviral treatment surface 3, as shown in fig. 5C, and the second active ingredient is present on the antibacterial and antiviral treatment surface 3.
The related technical details mentioned in the first and second embodiments are still valid in this embodiment, and in order to reduce repetition, a detailed description is omitted here. Accordingly, the related-art details mentioned in the present embodiment can also be applied to the first and second embodiments.
Antibacterial test
Experimental example 1: the structure of the test sample is shown in FIG. 3, in which 10g/m of porous substrate is present per unit surface area, in combination with an antibacterial and antiviral material 2 (ii) a second active ingredient (silver nitrate and titanium dioxide);
experimental example 2: the porous substrate (breathable foam cushion) combined with the antimicrobial and antiviral material, the test sample structure is shown in FIG. 1, wherein 15g/m of porous substrate per unit surface area 2 (ii) a first active ingredient (silver nitrate and zinc nitrate);
experimental example 3: the structure of the test sample is shown in FIG. 2, in which the porous substrate (breathable foam cushion) has 25g/m per unit surface area 2 Is composed of a first active ingredient (silver nitrate and zinc nitrate) and 7g/m 2 (ii) a second active ingredient (silver nitrate and titanium dioxide);
experimental example 4: the structure of the test sample is shown in FIG. 3, wherein 10g/m of the fiber substrate per unit surface area is present 2 (ii) a second active ingredient (silver nitrate and titanium dioxide);
experimental example 5: the structure of the test sample is shown in FIG. 1, wherein the fibrous substrate has 15g/m per unit surface area 2 (ii) a first active ingredient (silver nitrate and zinc nitrate);
experimental example 6: the structure of the test sample is shown in FIG. 2, wherein the fibrous substrate has a combined antibacterial and antiviral material, wherein 25g/m of the fibrous substrate per unit surface area 2 Is composed of a first active ingredient (silver nitrate and zinc nitrate) and 7g/m 2 (ii) a second active ingredient (silver nitrate and titanium dioxide);
comparative example 1: the test sample is an unprocessed porous substrate;
comparative example 2: the test sample was an unprocessed fibrous substrate.
The antibacterial experimental method of the porous substrate comprises the following steps:
e.coli was cultured in 1/500 nutrient solution (1/500 NB) at 37℃for 2 hours, and then 1/500NB was used to prepare E.coli solution at a concentration of 1.0 to 5.0X10 5 CFU/ml bacterial liquid, then 0.4ml bacterial liquid is dropped on the surface of the test sample, and 4.0X4.0 cm bacterial liquid is added 2 The PET film of (C) is covered on the bacterial liquid. After placing a test sample with bacterial liquid on the surface in a clean culture dish and culturing for 24 hours at 35 ℃, the PET film is taken down to collect bacterial liquid, and then the surface of the test sample is washed with 9.6ml of TSB nutrient solution for multiple times to wash off residual bacterial liquid. The bacterial liquid was mixed uniformly and diluted with PBS buffer, 1ml of diluted bacterial liquid was dropped into a Agar plate, and after the plate was coated, the culture was carried out at 35℃for 24 hours, and then the bacterial liquid was taken out to confirm the bacterial count, and the results are shown in Table 1.
The antibacterial experimental method for the fiber base material comprises the following steps:
the test specimen was weighed 2g and then sheared to 1.0X1.0 cm 2 The size is filled into a clean plastic tank. E.coli was cultured in TSB nutrient solution at 37℃for 1 hour, and then the E.coli solution was prepared to a concentration of 1.5 to 3.0X10 with PBS buffer 5 CFU/ml of bacterial liquid, from which 50ml of bacterial liquid was then poured into a plastic jar containing the test sample. After a plastic jar containing the bacterial liquid and the test sample was placed in a culture environment at 37 ℃ for shake culture for 5 hours, 1ml of the bacterial liquid was properly diluted with PBS buffer, 1ml of the diluted bacterial liquid was dropped into a Agar plate, the plate was incubated at 35 ℃ for 24 hours, and then the bacterial count was taken out for confirmation, and the results are shown in Table 2.
Discussion of antibacterial test results
The test results showed that the test sample (unprocessed porous substrate) of comparative example 1 had only 3.233% of antibacterial activity against E.coli, with no significant antibacterial effect. Under the same culture conditions (stationary culture for 24 hours under dark culture conditions), the test samples of experimental examples 1 to 3 all had very excellent antibacterial effects against E.coli with an antibacterial rate as high as 99.9999988%. Although the performance of the antibacterial ratio was not different (the same value) in experimental examples 1 to 3, it was found that the amount of the first active ingredient was larger than the amount of the second active ingredient in order to achieve the same antibacterial effect by comparing the amounts of the active ingredients; when the first active ingredient and the second active ingredient are used simultaneously as the antibacterial and antiviral material, the respective amounts of the first active ingredient and the second active ingredient can be reduced.
The test sample (unprocessed textile substrate) of comparative example 2 had an antibacterial efficiency against E.coli of only 15.44% and an antibacterial effect was poor; this value may be subject to errors because the bacteria card cannot elute all on the fiber. Under the same culture conditions (shake culture under dark culture conditions for 5 hours), the test samples of experimental examples 4 to 6 all have very excellent antibacterial effects on escherichia coli, and the antibacterial rate is as high as 99.99999187%. Although the performance of the antibacterial ratio was not different (the same value) in experimental examples 4 to 6, it was found that the amount of the first active ingredient was larger than the amount of the second active ingredient in order to achieve the same antibacterial effect by comparing the amounts of the active ingredients; in addition, when the first active ingredient and the second active ingredient are used simultaneously as the antibacterial and antiviral material, the respective amounts of the first active ingredient and the second active ingredient can be reduced.
Antiviral testing
Experimental example 1: the structure of the test sample is shown in FIG. 3, in which the porous substrate (breathable foam cushion) is combined with an antibacterial and antiviral material, wherein the porous substrate has a per unit tableThere is 30g/m of 2 Is irradiated with a UVA light source (wavelength 365nm, illuminance 0.25 mW/cm) during the test 2 )；
Experimental example 2: the porous substrate (breathable foam cushion) combined with the antimicrobial and antiviral material, the test sample structure is shown in FIG. 1, wherein 45g/m of porous substrate per unit surface area 2 Is not irradiated with UVA light source during the test;
experimental example 3: the structure of the test sample is shown in FIG. 2, in which the porous substrate (breathable foam cushion) has 20g/m per unit surface area 2 Is composed of a first active ingredient (silver nitrate and zinc nitrate) and 15g/m 2 (ii) the second active ingredient (silver nitrate and titanium dioxide) and not irradiated with UVA light source during the test;
experimental example 4: the structure of the test sample is shown in FIG. 3, wherein the fibrous substrate has 30g/m per unit surface area 2 Is irradiated with a UVA light source (illuminance 0.25mW/cm at 365nm wavelength) during the test 2 )；
Experimental example 5: the structure of the test sample is shown in FIG. 1, wherein 45g/m of the fiber substrate per unit surface area is present 2 Is not irradiated with UVA light source during the test;
experimental example 6: the structure of the test sample is shown in FIG. 2, wherein 20g/m of the fiber substrate per unit surface area is present 2 Is composed of a first active ingredient (silver nitrate and zinc nitrate) and 15g/m 2 (ii) the second active ingredient (silver nitrate and titanium dioxide) and not irradiated with UVA light source during the test;
comparative example 1: the unprocessed porous substrate was irradiated with UVA light source (wavelength 365nm, illuminance 0.25mW/cm during the test 2 )；
Comparative example 2: an unprocessed porous substrate, which is not irradiated with a UVA light source during the test;
comparative example 3: the unprocessed fibrous substrate was irradiated with a UVA light source (wavelength 365nm, illuminance 0.25mW/cm during the test 2 )；
Comparative example 4: the unprocessed fibrous substrate was not irradiated with UVA light during the test.
Method of illumination antiviral experiment for porous substrate (experimental example 1 and comparative example 1):
culturing H1N1 virus in MEM culture medium to a concentration of more than 1.0X10 8 After CFU/ml of virus solution, the solution is diluted by distilled water for 10 times after sterilization for standby. Then 0.4ml of diluted virus was dropped on the surface of the test sample, and 4.0X14.0 cm of the diluted virus was added 2 The PET film of (C) is covered on the virus liquid. The test sample with the virus liquid on the surface is kept stand for 4 hours at 25 ℃ under the irradiation of a UVA light source, then the virus liquid is taken out, the PET film is taken down to collect the virus liquid, then the surface of the test sample is washed by 9.6ml of eluent for a plurality of times to wash out the residual virus liquid, and finally the virus number calculation and confirmation are carried out by a plaque method, and the results are shown in Table 3.
Non-illuminated antiviral assay against porous substrates (experimental examples 2, 3 and comparative example 2):
culturing H1N1 virus in MEM culture medium to a concentration of more than 1.0X10 8 After CFU/ml of virus solution, the solution is diluted by distilled water for 10 times after sterilization for standby. Then 0.4ml of diluted virus was dropped on the surface of the test sample, and 4.0X14.0 cm of the diluted virus was added 2 The PET film of (C) is covered on the virus liquid. The test sample with virus liquid on the surface was left standing at 25℃for 24 hours, then taken out, the PET film was removed to collect the virus liquid, then the surface of the test sample was washed with 9.6ml of eluent in several times to wash out the residual virus liquid, and finally the virus count was calculated and confirmed by the plaque method, and the results are shown in Table 3.
Method of photoperiod test against fiber substrate (comparative experiment 1 and comparative example 3):
the test specimen was weighed 0.4g and then sheared to 1.0X1.0 cm 2 The materials are stacked into a clean glass culture dish after the materials are in size. H1N1 virus was cultured in MEM medium to a concentration of more than 1.0X10 8 After CFU/ml of virus solution, sterilizing and steamingDiluting distilled water for 10 times. Then 0.2ml of diluted virus was dropped on the surface of the test sample, and the test sample was covered with a glass petri dish. The coated test samples were allowed to stand at 25℃for 2 hours under irradiation with a UVA light source, then were taken out, the virus liquid in the glass culture dish was sufficiently eluted with 20ml of an eluent, and finally, the virus count was calculated and confirmed by the plaque method, and the results are shown in Table 4.
Non-illuminated antiviral assay against fibrous substrate (comparative examples 2, 3 and 4):
the test specimen was weighed 0.4g and then sheared to 1.0X1.0 cm 2 The materials are stacked into a clean glass culture dish after the materials are in size. H1N1 virus was cultured in MEM medium to a concentration of more than 1.0X10 8 After CFU/ml of virus solution, the solution is diluted by distilled water for 10 times after sterilization for standby. Then 0.2ml of diluted virus was dropped on the surface of the test sample, and the test sample was covered with a glass petri dish. The coated test sample was allowed to stand at 25℃for 24 hours, then was taken out, the virus liquid in the glass culture dish was sufficiently eluted with 20ml of the eluent, and finally, the virus count was confirmed by the plaque method, and the results are shown in Table 4.
Discussion of antiviral test results
The test results showed that the green porous substrate (comparative example 1) had only 18.70% antiviral activity against H1N1 virus under UVA light source irradiation, but the virus showed poor antiviral activity although it was slightly reduced by UVA irradiation. In contrast, the test sample of experimental example 1 has very excellent antiviral effect on H1N1 virus, and the antiviral rate is as high as 99.86%. In addition, the antiviral rate of the green porous substrate (comparative example 2) against H1N1 virus was only 8.79% under dark conditions without light, and no antiviral efficacy was evident. In contrast, the test samples of experimental examples 2 and 3 have very excellent antiviral effects on H1N1 viruses, and the antiviral rates reach 99.95% and 99.98% respectively.
Under the irradiation condition of the UVA light source, the antiviral rate of the unprocessed textile substrate (comparative example 3) to the H1N1 virus is only 3.3 percent, and the antiviral rate is not good although the virus is slightly reduced due to the irradiation of the UVA. In contrast, the test sample of experimental example 4 has very excellent antiviral effect against H1N1 virus, and the antiviral rate is as high as 99.5%. In addition, the antiviral rate of the raw fiber substrate (comparative example 4) against H1N1 virus was only 2.76% under dark conditions without light, and no antiviral efficacy was evident. In contrast, the test sample of experimental example 1 has very excellent antiviral effect on H1N1 virus, and the antiviral rate is as high as 99.86%. The test samples of experimental examples 5 and 6 have very excellent antiviral effects on H1N1 viruses, and the antiviral rates respectively reach 99.29% and 99.74%.
It can be seen that the second active ingredient (metallic silver and titanium dioxide) can provide a porous or fibrous substrate with very good antiviral efficacy under UVA light irradiation conditions, while the second active ingredient or the combination of the first and second active ingredients can provide a porous or fibrous substrate with very good antiviral efficacy under non-illuminated dark conditions. Comparing the antibacterial and antiviral test results, it can be seen that a greater amount of the first active ingredient and/or the second active ingredient is required to achieve the desired antiviral effect.
Advantageous effects of the embodiments
The antibacterial and antiviral structure of the present invention can be bonded to the porous substrate by "the antibacterial and antiviral material is present in an amount of 1 to 450g/m per unit surface area of the porous substrate 2 The antibacterial and antiviral material of (a) and (b) comprises at least one of a first active ingredient and a second active ingredient, wherein the first active ingredient comprises a silver component and a zinc-containing compound, and the second active ingredient comprises a silver component and titanium dioxide, so that the antibacterial rate and the antiviral rate are both over 99%. In addition, the antibacterial and antiviral structure of the invention has the advantages of suitabilityWide application range, flexible and convenient use, no harm to human body and environment, etc.
The foregoing disclosure is only a preferred embodiment of the present invention and is not intended to limit the scope of the claims, so that all equivalent technical changes made by the application of the present invention and the accompanying drawings are included in the scope of the claims.
Claims (11)
1. An antimicrobial and antiviral structure comprising a porous substrate and an antimicrobial and antiviral material bonded to the porous substrate, the antimicrobial and antiviral material comprising at least one of a first active ingredient and a second active ingredient;
wherein the first active ingredient comprises a silver component and a zinc-containing compound, and the second active ingredient comprises a silver component and titanium dioxide;
wherein the porous substrate has 1-450g/m per unit surface area 2 Is a material having antibacterial and antiviral properties.
2. The antimicrobial antiviral structure of claim 1, further comprising an outer coating covering an outer surface of the porous substrate; wherein the first active ingredient is present in the outer cover when the antibacterial and antiviral material comprises only the first active ingredient.
3. The antimicrobial and antiviral structure of claim 1 further comprising an outer cover layer covering an outer surface of the porous substrate, the outer cover layer having an antimicrobial and antiviral treated surface; wherein when the antibacterial and antiviral material contains both the first active ingredient and the second active ingredient, the first active ingredient is present in the outer cover and the second active ingredient is present on the antibacterial and antiviral treated surface.
4. An antimicrobial and antiviral structure according to claim 2 or claim 3 wherein the outer coating is formed from a first composition comprising the first active ingredient and a film-forming polymer; wherein the silver component of the first active ingredient is contained in the first composition in an amount of 10ppm to 1000ppm, and the zinc-containing compound of the first active ingredient is contained in an amount of 1wt% to 10wt% and the film-forming polymer is contained in an amount of 5wt% to 20wt% based on 100wt% of the first composition.
5. The antimicrobial antiviral structure of claim 4, wherein the film-forming polymer is acrylic, polyurethane, or polycarbonate.
6. An antimicrobial antiviral structure according to claim 3 wherein said antimicrobial antiviral treatment surface is formed by applying a second composition to an outer surface of said outer cover, said second composition comprising said second active ingredient and water; wherein the silver component of the second active ingredient is contained in an amount of 0.001 to 1wt% and the titanium dioxide of the second active ingredient is contained in an amount of 0.01 to 2wt% based on 100wt% of the second composition.
7. The antimicrobial and antiviral structure of claim 1 wherein the porous substrate is comprised of a plurality of base fibers attached with the antimicrobial and antiviral material.
8. The antimicrobial antiviral structure of claim 7, wherein a plurality of said base fibers are each coated with an outer coating; wherein when the antibacterial and antiviral material contains only the first active ingredient, the first active ingredient is present in the outer cover of a plurality of the base fibers.
9. The antimicrobial and antiviral structure of claim 7 wherein a plurality of said base fibers are each covered by an outer cover, said outer cover having an antimicrobial and antiviral treated surface; wherein when the antibacterial and antiviral material contains both the first active ingredient and the second active ingredient, the first active ingredient is present in the outer coating layers of the plurality of base fibers, and the second active ingredient is present on the antibacterial and antiviral treated surface of the outer coating layers of the plurality of base fibers.
10. The antimicrobial and antiviral structure according to any one of claims 1 to 4 and 8 to 9, wherein the zinc-containing compound of the first active ingredient is selected from zinc nitrate, sodium tetrahydroxy zincate, zinc chloride, zinc citrate, zinc undecylenate, zinc oxalate, zinc acetate, zinc carbonate, zinc iodide, zinc bromide, zinc pyrithione, zinc oxide, zinc ricinoleate, zinc borate, or zinc perchlorate.
11. The antimicrobial and antiviral structure according to any one of claims 1, 3, 6, and 9 wherein the titanium dioxide of the second active ingredient is in the form of particles and has a major axis of 10nm to 50nm and a minor axis of 3nm to 20nm.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111410009.6A CN116162282A (en) | 2021-11-24 | 2021-11-24 | Antibacterial and antiviral structure |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111410009.6A CN116162282A (en) | 2021-11-24 | 2021-11-24 | Antibacterial and antiviral structure |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN116162282A true CN116162282A (en) | 2023-05-26 |
Family
ID=86415093
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202111410009.6A Pending CN116162282A (en) | 2021-11-24 | 2021-11-24 | Antibacterial and antiviral structure |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN116162282A (en) |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2017000655A (en) * | 2015-06-16 | 2017-01-05 | 日本板硝子株式会社 | Substrate with antiviral thin film |
| JP2020040267A (en) * | 2018-09-10 | 2020-03-19 | イビデン株式会社 | Functional member |
| CN111484710A (en) * | 2020-05-12 | 2020-08-04 | 同曦集团有限公司 | Antibacterial and antiviral master batch for transparent mask, preparation method of antibacterial and antiviral master batch and antibacterial and antiviral transparent mask |
| CN211862382U (en) * | 2020-02-28 | 2020-11-06 | 同曦集团有限公司 | Antibacterial, antiviral and mildewproof crawling pad for children |
| CN113291002A (en) * | 2021-03-10 | 2021-08-24 | 广东茂业医疗科技有限公司 | Antibacterial and antiviral mask containing cuprous oxide |
| CN113667406A (en) * | 2020-05-13 | 2021-11-19 | 新福光涂装工程股份有限公司 | Antibacterial coating, preparation method of antibacterial coating, antibacterial coating and antiviral adhesive tape |
-
2021
- 2021-11-24 CN CN202111410009.6A patent/CN116162282A/en active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2017000655A (en) * | 2015-06-16 | 2017-01-05 | 日本板硝子株式会社 | Substrate with antiviral thin film |
| JP2020040267A (en) * | 2018-09-10 | 2020-03-19 | イビデン株式会社 | Functional member |
| CN211862382U (en) * | 2020-02-28 | 2020-11-06 | 同曦集团有限公司 | Antibacterial, antiviral and mildewproof crawling pad for children |
| CN111484710A (en) * | 2020-05-12 | 2020-08-04 | 同曦集团有限公司 | Antibacterial and antiviral master batch for transparent mask, preparation method of antibacterial and antiviral master batch and antibacterial and antiviral transparent mask |
| CN113667406A (en) * | 2020-05-13 | 2021-11-19 | 新福光涂装工程股份有限公司 | Antibacterial coating, preparation method of antibacterial coating, antibacterial coating and antiviral adhesive tape |
| CN113291002A (en) * | 2021-03-10 | 2021-08-24 | 广东茂业医疗科技有限公司 | Antibacterial and antiviral mask containing cuprous oxide |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI540111B (en) | Antimicrobial action of cu, cuo and cu2o nanoparticles on glass surfaces and durable coatings | |
| EP2012839B1 (en) | Novel antimicrobial substrates and uses thereof | |
| US20060141015A1 (en) | Antimicrobial material | |
| US20080085326A1 (en) | Antimicrobial material compositions enriched with different active oxygen species | |
| CN106924803B (en) | A kind of high-performance medical use liquid adhesive bandage and preparation method thereof | |
| JP2016506350A (en) | Glass frit antibacterial coating | |
| CN105310850B (en) | Incubator, the hydrophilic processing piece of incubator and the hydrophilic processing antibacterial film of incubator that incubator covers, has the cover | |
| JP2008514630A (en) | Antibacterial silver halide composition | |
| CA2965978A1 (en) | Composition and method to form a self decontaminating surface | |
| CN102671239A (en) | Method for preparing broad-spectrum antibacterial effect chitosan nano composite gel coating | |
| Asghari et al. | Imparting commercial antimicrobial dressings with low-adherence to burn wounds | |
| Marković et al. | The influence of coating with aminopropyl triethoxysilane and CuO/Cu2O nanoparticles on antimicrobial activity of cotton fabrics under dark conditions | |
| CN113712028A (en) | Photoluminescent long-acting film-forming disinfection composition and preparation method and application thereof | |
| CN114606767B (en) | Preparation method of broad-spectrum antibacterial polypropylene non-woven fabric | |
| Haufe et al. | Biocidal nanosol coatings | |
| Jia et al. | PHMG-KH560 as antifungal and reinforcement media for paper materials | |
| CN116162282A (en) | Antibacterial and antiviral structure | |
| CN202062729U (en) | Biological antibacterial non-woven fabric | |
| JPH08209064A (en) | Antimicrobial coating material for fancy plywood | |
| TWI821791B (en) | Antibacterial and antiviral structure | |
| CN105745074B (en) | Base material, antibiotic slice, radiographic equipment, contact panel with antibiotic layer | |
| CN115814141A (en) | Medical dressing with antibacterial and anti-adhesion functions and preparation method thereof | |
| CN110507848A (en) | Carry enzyme bacteria cellulose base composite antibiotic aerogel dressing and preparation method thereof | |
| KR20170025622A (en) | Mask with enhanced functions using antibiosis of oxidized graphene and photocatalysis | |
| Tabbasum et al. | Sol–gel nanocomposite coatings for preventing biofilm formation on contact lens cases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |